Dainippon Sumitomo Pharma founds SIREGE, a company focused on iPS-based therapy for macular degeneration

The company SIREGE (for SIght REGEneration) is a joint venture with RIKEN’s spin-out HEALIOS and located on Kobe’s Port Island, close to RIKEN’s Center for Developmental Biology where the studies on regeneration of retinal pigment epithelial cells from autologous iPS cells are being done. In China, > 6 % of people over 60 develop macular degeneration.

China Bio news release, March 10, 2014

Most popular posts: